Optic IconOptic Logo
|
SearchCollectionsBenchmarks

ADT

3 clinical trials

20 abstracts

1 indication

Indication
Prostate Cancer
Clinical trial
Tracer-Based Image Guided Surgery for Recurrent Prostate Cancer: A Prospective Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-11-01
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).
Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
Org: Janssen Research & Development, Brisbane, CA, Hospital Aranda de la Parra, Guanajuato, Mexico, West China Hospital of Sichuan University, Sichuan, China, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY, Janssen Research & Development, Titusvillle, NJ,
Abstract
A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).
Org: Froedtert & Medical College of Wisconsin, Department of Neurobiology and Anatomy,
Abstract
Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805).
Org: University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, University College London, London, United Kingdom, South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia,
Abstract
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
Org: Saint Louis VA Medical Center, University of Massachusetts Lowell, St. Louis Veterans Affairs Medical Center,
Abstract
Randomized  PROSTATE-IQ trial to reduce ADT treatment burden for patients with biochemical recurrence after prostatectomy.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).
Org: Monash University Eastern Health Clinical School, Monash Cancer Centre, Sydney Adventist Hospital, Mater Misercordiae University Hospital, Guy's, King's, and St. Thomas' Hospitals, and Sarah Cannon Research Institute,
Abstract
A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.
Org: Northwestern University, Feinberg School of Medicine,
Abstract
Apa-RP: Multicenter phase 2 study of apalutamide (Apa) and androgen deprivation therapy (ADT) for the treatment of high-risk localized prostate cancer (HR LPC) following radical prostatectomy (RP)—Results in Black and non-Black patients (pts).
Org: MidLantic Urology LLC, Janssen Medical Affairs, Janssen Biotech Inc,
Clinical trial
A Phase I/II Study of M9241 With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and M9241 With Docetaxel in Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-13
Abstract
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
Org: Gustave Roussy Institute, Bergonié Institute, Léon Bérard Cancer Center, Institut de Cancérologie de l'Ouest, Azuréen Center of Oncology,
Abstract
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.
Org: Artera, Vancouver, BC, Canada, Department of Pathology, University of California San Francisco, San Francisco, CA, Tulane University, New Orleans, LA, University of California, San Francisco, San Francisco, CA, Case Western Reserve University, Cleveland, OH,
Abstract
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
Org: Dana-Farber Cancer Institute, St. Luke’s Hospital, Division of Urology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Tor Vergata University of Rome,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
Org: Janssen Research & Development, Cambridge, MA, Janssen Research & Development, Spring House, PA, Janssen Research & Development, Titusville, NJ, Janssen Research & Development, Los Angeles, CA, Janssen Research & Development, Raritan, NJ,
Abstract
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
Org: Carolina Urologic Research Center, Northwestern University Feinberg School of Medicine, Brigham and Women’s Hospital, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Michigan,
Abstract
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.
Org: Global Drug Development, Novartis Pharmaceuticals AG, Basel, Switzerland,
Abstract
Androgen-deprivation therapy and risk of dementia in patients with prostate cancer: Clinical outcomes from real-world data.
Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Seidman Cancer Center, Johns Hopkins University - School of Medicine,
Abstract
Nutritional program among patients with prostate cancer receiving androgen deprivation therapy (ADT).
Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Brasília, Brazil, Brazil, Brasilia, Brazil, Centro de Cancer de Brasilia,
Abstract
Castration-resistant prostate cancer (CRPC) on PSMA-PET: Imaging features, disease distribution, and a comparison to castration-sensitive prostate cancer (CSPC).
Org: Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Hospital of the University of Pennsylvania, Abramson Cancer Center and Perelman School of Medicine,